Second Faculty of Medicine, Department of Neurology, Charles University and University Hospital Motol, Prague, Czech Republic.
First Faculty of Medicine, Department of Neurology and Center of Clinical Neuroscience, Charles University and General University Hospital, Prague, Czech Republic.
PLoS One. 2021 Dec 14;16(12):e0260601. doi: 10.1371/journal.pone.0260601. eCollection 2021.
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by disease-associated variants in the alpha-galactosidase A gene (GLA). FD is a known cause of stroke in younger patients. There are limited data on prevalence of FD and stroke risk in unselected stroke patients.
A prospective nationwide study including 35 (78%) of all 45 stroke centers and all consecutive stroke patients admitted during three months. Clinical data were collected in the RES-Q database. FD was diagnosed using dried blood spots in a stepwise manner: in males-enzymatic activity, globotriaosylsphingosine (lyso-Gb3) quantification, if positive followed by GLA gene sequencing; and in females GLA sequencing followed by lyso-Gb3.
986 consecutive patients (54% men, mean age 70 years) were included. Observed stroke type was ischemic 79%, transient ischemic attack (TIA) 14%, intracerebral hemorrhage (ICH) 7%, subarachnoid hemorrhage 1% and cerebral venous thrombosis 0.1%. Two (0.2%, 95% CI 0.02-0.7) patients had a pathogenic variant associated with the classical FD phenotype (c.1235_1236delCT and p.G325S). Another fourteen (1.4%, 95% CI 0.08-2.4) patients had a variant of GLA gene considered benign (9 with p.D313Y, one p.A143T, one p.R118C, one p.V199A, one p.R30K and one p.R38G). The index stroke in two carriers of disease-associated variant was ischemic lacunar. In 14 carriers of GLA gene variants 11 strokes were ischemic, two TIA, and one ICH. Patients with positive as compared to negative GLA gene screening were younger (mean 60±SD, min, max, vs 70±SD, min, max, P = 0.02), otherwise there were no differences in other baseline variables.
The prevalence of FD in unselected adult patients with acute stroke is 0.2%. Both patients who had a pathogenic GLA gene variant were younger than 50 years. Our results support FD screening in patients that had a stroke event before 50 years of age.
法布里病(FD)是一种罕见的 X 连锁溶酶体贮积症,由α-半乳糖苷酶 A 基因(GLA)中的疾病相关变异引起。FD 是年轻患者中风的已知病因。在未选择的中风患者中,FD 的患病率和中风风险的数据有限。
一项前瞻性全国性研究包括 35 个(78%)所有 45 个中风中心和三个月内连续收治的所有中风患者。临床数据在 RES-Q 数据库中收集。FD 采用逐步方法通过干血斑进行诊断:男性-酶活性、神经酰胺三己糖苷(lyso-Gb3)定量,如果阳性,随后进行 GLA 基因测序;女性则进行 GLA 测序,然后进行 lyso-Gb3。
纳入 986 例连续患者(54%为男性,平均年龄 70 岁)。观察到的中风类型为缺血性 79%,短暂性脑缺血发作(TIA)14%,脑出血(ICH)7%,蛛网膜下腔出血 1%,脑静脉血栓形成 0.1%。两名(0.2%,95%CI 0.02-0.7)患者存在与经典 FD 表型相关的致病性变异(c.1235_1236delCT 和 p.G325S)。另外 14 名(1.4%,95%CI 0.08-2.4)患者携带 GLA 基因的变异被认为是良性的(9 名携带 p.D313Y,1 名携带 p.A143T,1 名携带 p.R118C,1 名携带 p.V199A,1 名携带 p.R30K,1 名携带 p.R38G)。携带疾病相关变异的两名患者的首发中风为缺血性腔隙性。在携带 GLA 基因突变的 14 名患者中,11 例为缺血性中风,2 例为 TIA,1 例为 ICH。与 GLA 基因筛查阴性相比,阳性患者更年轻(平均 60±SD,min,max,vs 70±SD,min,max,P=0.02),否则其他基线变量无差异。
在未选择的急性中风成年患者中,FD 的患病率为 0.2%。两名携带致病性 GLA 基因突变的患者均小于 50 岁。我们的结果支持在 50 岁以下发生中风事件的患者中进行 FD 筛查。